Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab added to DHAP/VIM reinduction and autologous stem cell transplantation for relapsed or progressive B-cell non-Hodgkin lymphoma
ISRCTN95614846Phase 3Completed
- Sponsor
- HOVON
- Start
- Nov 2000
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in mature B-cell lymphoma (2 arms), sponsored by HOVON. Primary endpoint: Overall survival. Started Nov 2000; status: completed.
02
Drugs
rituximab
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on ISRCTN95614846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN95614846.